QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, November 26, 2003, 23(34):10982-10987

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (19) Citing Articles via Google Scholar Google Scholar Articles by Alfinito, P. D. Articles by Sonsalla, P. K. Search for Related Content PubMed PubMed Citation Articles by Alfinito, P. D. Articles by Sonsalla, P. K.

 Previous Article  |  Next Article 

BRIEF COMMUNICATION
Adenosinergic Protection of Dopaminergic and GABAergic Neurons against Mitochondrial Inhibition through Receptors Located in the Substantia Nigra and Striatum, Respectively

Peter D. Alfinito, Sheng-Ping Wang, Lawrence Manzino, Sonia Rijhsinghani, Gail D. Zeevalk, and Patricia K. Sonsalla

Levine Neuroscience Laboratory, Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, New Jersey 08854

Mitochondrial dysfunction may contribute to dopaminergic (DAergic) cell death in Parkinson's disease and GABAergic cell death in Huntington's disease. In the present work, we tested whether blocking A₁ receptors could enhance the damage to DAergic and GABAergic neurons caused by mitochondrial inhibition, and whether blocking A_2a receptors could protect against damage in this model. Animals received an intraperitoneal injection of 8-cyclopentyl-1,3-dipropylxanthine (CPX) (A₁ antagonist) or 3,7-dimethyl-1-propargylxanthine (DMPX) (A_2a antagonist) 30 min before intrastriatal infusion of malonate (mitochondrial complex II inhibitor). Damage was assessed 1 week later by measuring striatal dopamine, tyrosine hydroxylase (TH), and GABA content. In mice and rats, malonate-induced depletion of striatal dopamine, TH, or GABA was potentiated by pretreatment with 1 mg/kg CPX and attenuated by pretreatment with 5 mg/kg DMPX. To determine the location of the A₁ and A_2a receptors mediating these effects, CPX or DMPX was infused directly into the striatum or substantia nigra of rats 30 min before intrastriatal infusion of malonate. When infused into the striatum, CPX (20 ng) potentiated, whereas DMPX (50 ng) prevented malonate-induced GABA loss, but up to 100 ng of CPX or 500 ng of DMPX did not alter malonate-induced striatal dopamine loss. Intranigral infusion of CPX (100 ng) or DMPX (500 ng), however, did exacerbate and protect, respectively, against malonate-induced striatal dopamine loss. Thus, A₁ receptor blockade enhances and A_2a receptor blockade protects against damage to DAergic and GABAergic neurons caused by mitochondrial inhibition. Interestingly, these effects are mediated by A₁ and A_2a receptors located in the substantia nigra for DAergic neurons and in the striatum for GABAergic neurons.

Key words: Parkinson's disease; Huntington's disease; neuroprotection; adenosine receptors; A_2a antagonist; A₁ antagonist; malonate

---

Received Aug 5, 2003; revised October 14, 2003; accepted October 15, 2003.

This article has been cited by other articles:

				L. Y. Moy, S.-P. Wang, and P. K. Sonsalla Mitochondrial Stress-Induced Dopamine Efflux and Neuronal Damage by Malonate Involves the Dopamine Transporter J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 747 - 756. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help